Deutsche Bank AG Has $24.52 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Deutsche Bank AG grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 17.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 274,134 shares of the medical equipment provider's stock after purchasing an additional 40,866 shares during the quarter. Deutsche Bank AG owned approximately 0.39% of Lantheus worth $24,524,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Kestra Investment Management LLC bought a new position in Lantheus during the 4th quarter worth approximately $27,000. Summit Securities Group LLC bought a new position in shares of Lantheus during the fourth quarter worth $37,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Parkside Financial Bank & Trust increased its position in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares in the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in Lantheus during the 4th quarter worth $125,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on LNTH shares. B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Truist Financial lowered their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $132.67.

Lantheus Stock Down 1.4%

Shares of NASDAQ:LNTH traded down $1.13 during mid-day trading on Tuesday, reaching $77.13. 239,262 shares of the stock were exchanged, compared to its average volume of 979,579. The stock's 50 day simple moving average is $96.65 and its 200-day simple moving average is $92.87. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The company has a market cap of $5.34 billion, a P/E ratio of 12.83 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same quarter in the previous year, the company posted $1.69 EPS. The business's revenue was up .8% on a year-over-year basis. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.